Clinical Trials
Advancing Urology Through Research
We’re keeping Southeast Michigan at the forefront of urology care, and giving patients access to promising treatments and diagnostics, with our robust clinical research.
Each clinical trial follows strict guidelines to protect participants. Ask your doctor if there’s a trial that is right for you. Or call our Clinical Research Department at 248-786-0467.
Explore These Clinical Trials at Michigan Institute of Urology
Clinical research trials play an essential role in bringing new treatments and diagnostics to our patients. By participating you’ll gain the reassurance and security of being closely monitored, and the satisfaction of knowing that you’re playing an important role in advancing medicine.
These clinical trials are currently available at Michigan Institute of Urology.
ABLE-22
Ferring Pharmaceuticals
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination with Chemotherapy or Immunotherapy in Participants with High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
CORE-008
CG Oncology, Inc.
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
EvoPAR-PR01
AstraZenenca
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
LEGION-100
Syncromune, Inc.
A Phase 1b Open-Label, Dose-Escalation Study of SYNC-T Therapy SV-102 in Patients Diagnosed With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PIVOT-006
CG Oncology, Inc.
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
ProvONE
Dendreon
An Open-Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response
